A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Irreversible cell growth arrest, a process termed cellular senescence, is emerging as an intrinsic tumor suppressive mechanism. Oncogene-induced senescence is thought to be invariably preceded by hyperproliferation, aberrant replication, and activation of a DNA damage checkpoint response (DDR), rendering therapeutic enhancement of this process unsuitable for cancer treatment. We previously demonstrated in a mouse model of prostate cancer that inactivation of the tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (Pten) elicits a senescence response that opposes tumorigenesis. Here, we show that Pten-loss-induced cellular senescence (PICS) represents a senescence response that is distinct from oncogene-induced senescence and can be targeted for cancer therapy. Using mouse embryonic fibroblasts, we determined that PICS occurs rapidly after Pten inactivation, in the absence of cellular proliferation and DDR. Further, we found that PICS is associated with enhanced p53 translation. Consistent with these data, we showed that in mice p53-stabilizing drugs potentiated PICS and its tumor suppressive potential. Importantly, we demonstrated that pharmacological inhibition of PTEN drives senescence and inhibits tumorigenesis in vivo in a human xenograft model of prostate cancer. Taken together, our data identify a type of cellular senescence that can be triggered in nonproliferating cells in the absence of DNA damage, which we believe will be useful for developing a "pro-senescence" approach for cancer prevention and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although initially PTEN loss-induced cellular senescence was not associated with DDR activation40, it was later found to be associated with hyperproliferation, DDR engagement and cellular senescence in vivo41”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“However, despite this, DDR markers have a limited potential for identifying senescent cells in vivo since DDR independent mechanisms are also capable of inducing senescence via p53/p21WAF1/CIP1 pathway (Alimonti et al., 2010; Freund et al., 2011; Muñoz-Espín et al., 2013; Storer et al., 2013; Salama et al., 2014).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Alimonti et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“pharmacological inhibition of PTEN in prostate cancer that is wild type for TP53, results in the inhibition of tumorigenesis with senescence induction in a human xenograft model 152”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“TP53 up-regulation upon PTEN inhibition appears to be dependent on mTOR activity, which increases TP53 translation 152”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“unlike OIS, PICS occurs in the absence of transient hyper-proliferation and a DNA damage response (DDR) 152”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [152]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Small molecule–based reversible reprogramming of cellular lifespan
Won, J., Kim, M. K., Kim, N., Ahn, J. H., Lee, W. G., Kim, S. S., Chang, K.-Y., Yi, Y.-W., & Kim, T. K. (2006) · Nature Chemical Biology · doi:10.1038/nchembio800 · Cited by 74
RetractedJemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Self-citationOncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication
Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra, C., Garre’, M., Giovanni Nuciforo, P., Bensimon, A., et al. (2006) · Nature · doi:10.1038/nature05327 · Cited by 1,821
Pten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516
Self-citationSenescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Oncogene-induced senescence as an initial barrier in lymphoma development
Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H. F. M., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2005) · Nature · doi:10.1038/nature03841 · Cited by 1,220
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Self-citationMajumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
A PCR primer bank for quantitative gene expression analysis
Wang, X. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng154 · Cited by 859
Pten Dose Dictates Cancer Progression in the Prostate
Trotman, L. C., Niki, M., Dotan, Z. A., Koutcher, J. A., Di Cristofano, A., Xiao, A., Khoo, A. S., Roy-Burman, P., Greenberg, N. M., Dyke, T. V., et al. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000059 · Cited by 676
Self-citationp19ARF links the tumour suppressor p53 to Ras
Palmero, I., Pantoja, C., & Serrano, M. (1998) · Nature · doi:10.1038/25870 · Cited by 615
(2003) · PubMed · Cited by 608
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis
Ruggero, D., Montanaro, L., Ma, L., Xu, W., Londei, P., Cordon-Cardo, C., & Pandolfi, P. P. (2004) · Nature Medicine · doi:10.1038/nm1042 · Cited by 586
Self-citationAn inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse
Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., & P Pandolfi, P. (2001) · Nature Genetics · doi:10.1038/84879 · Cited by 498
Self-citationDose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis
Sarkisian, C. J., Keister, B. A., Stairs, D. B., Boxer, R. B., Moody, S. E., & Chodosh, L. A. (2007) · Nature Cell Biology · doi:10.1038/ncb1567 · Cited by 490
Gangloff, Y.-G., Mueller, M., Dann, S. G., Svoboda, P., Sticker, M., Spetz, J.-F., Um, S. H., Brown, E. J., Cereghini, S., Thomas, G., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9508-9516.2004 · Cited by 485
Self-citationMMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
Teng, D., Hu, R. H., Lin, H., Davis, T., Iliev, D., Frye, C., Swedlund, B., Hansen, K. L., Vinson, V. L., Gumpper, K. L., et al. (1997) · PubMed · Cited by 463
The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence
Mallette, F. A., Gaumont-Leclerc, M.-F., & Ferbeyre, G. (2007) · Genes & Development · doi:10.1101/gad.1487307 · Cited by 406
Identification of a tumour suppressor network opposing nuclear Akt function
Trotman, L. C., Alimonti, A., Scaglioni, P. P., Koutcher, J. A., Cordon-Cardo, C., & Pandolfi, P. P. (2006) · Nature · doi:10.1038/nature04809 · Cited by 394
Self-citationp53 is mutated in a subset of advanced-stage prostate cancers.
Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F. E., & Allred, D. C. (1993) · PubMed · Cited by 362
Suppressing Cancer: The Importance of Being Senescent
Campisi, J. (2005) · Science · doi:10.1126/science.1116801 · Cited by 249
Clinical significance of p53 alterations in surgically treated prostate cancers
Schlomm, T., Iwers, L., Kirstein, P., Jessen, B., Köllermann, J., Minner, S., Passow-Drolet, A., Mirlacher, M., Milde-Langosch, K., Graefen, M., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.104 · Cited by 196
Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA
Kim, J.-S., Lee, C., Bonifant, C. L., Ressom, H., & Waldman, T. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00537-06 · Cited by 161
A Small-Molecule Inhibitor for Phosphatase and Tensin Homologue Deleted on Chromosome 10 (PTEN)
Rosivatz, E., Matthews, J. G., McDonald, N. Q., Mulet, X., Ho, K. K., Lossi, N. S., Schmid, A. C., Mirabelli, M., Pomeranz, K. M., Erneux, C., et al. (2006) · ACS Chemical Biology · doi:10.1021/cb600352f · Cited by 153
Self-citationBreaking news: high-speed race ends in arrest – how oncogenes induce senescence
Micco, R. D., Fumagalli, M., & di Fagagna, F. D. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.07.012 · Cited by 90
mTOR and cancer: reason for dancing at the crossroads?
THOMAS, G. V. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.12.003 · Cited by 82
Self-citationMartinez, L. A., Yang, J., Vazquez, E. S., del Carmen Rodriguez-Vargas, M., Olive, M., Hsieh, J.-T., Logothetis, C. J., & Navone, N. M. (2002) · Carcinogenesis · doi:10.1093/carcin/23.8.1289 · Cited by 80
Differential p53-Independent Outcomes of p19 Arf Loss in Oncogenesis
Chen, Z., Carracedo, A., Lin, H., Koutcher, J. A., Behrendt, N., Egia, A., Alimonti, A., Carver, B. S., Gerald, W. L., Teruya‐Feldstein, J., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000053 · Cited by 74
Self-citationAgell, L., Hernandez, S., de Muga, S., Lorente, J., Juanpere, N., Esgueva, R., Serrano, S., Gelabert, A., & Lloreta, J. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.145 · Cited by 49
Isolation of Polysomal RNA for Microarray Analysis
Arava, Y. (2003) · Functional Genomics · doi:10.1385/1-59259-364-x:79 · Cited by 38
Research works printed but not linked: 5
- Teng, 1997, Cancer Res., 57, 5221
- Bookstein, 1993, Cancer Res., 53, 3369
- Chen, 2009, Sci Signal., 2, ra44
- Roninson, 2003, Cancer Res., 63, 2705
- Arava, 2003, Methods Mol Biol., 224, 79
Cited by
Aging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954
Cellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
Rubinsztein, D. C., Mariño, G., & Kroemer, G. (2011) · Cell · doi:10.1016/j.cell.2011.07.030 · Cited by 2,107
“PICS depends on the activation or mTOR and can be potentiated by inhibition of MDM2, which leads to an increase in p53 expression (Alimonti et al., 2010) and can be expected to inhibit autophagy (Tasdemir et al., 2008).”
BackgroundFour faces of cellular senescence
Rodier, F., & Campisi, J. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009094 · Cited by 2,070
“Cells also senesce without a DDR upon loss of the Pten tumor suppressor, a phosphatase that counteracts pro-proliferative/pro-survival kinases (Alimonti et al., 2010).”
Metadata
- Authors
- Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G., Rosivatz, E., Woscholski, R., Cognetti, F., Scher, H. I., & Pandolfi, P. P.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Cincinnati (US)
- Imperial College London (GB)
- Instituto Nazionale Tumori Regina Elena (IT)
- Corresponding author
- Pandolfi, Pier Paolo
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2010-03-01
- Volume
- 120
- Issue
- 3
- Pages
- 681-693
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2827955
- OpenAlex
- W2005250235
- Cited by
- 374
- References
- 46
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 23 · 2023: 12 · 2022: 24 · 2021: 18 · 2020: 30 · 2019: 17 · 2018: 27 · 2017: 17 · 2016: 20 · 2015: 20 · 2014: 28 · 2013: 25 · 2012: 27
- FWCI
- 23.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Iris (University of Trento) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Prostate Cancer Foundation
- American-Italian Cancer Foundation
- Associazione Italiana di Oncologia Medica
- National Institutes of Health
- National Cancer Institute (R01CA137050)
- National Institute on Minority Health and Health Disparities (R01MD004038)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- cellular senescence, PTEN inactivation, prostate cancer, tumor suppression, DNA damage response, non-proliferating cells, tumor xenografts
- MeSH terms
- Animals, Disease Models, Animal, DNA Damage, Embryo, Mammalian, Fibroblasts, Humans, Male, Neoplasm Transplantation, Prostatic Neoplasms, Protein Biosynthesis, Transplantation, Heterologous, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Cellular Senescence, Mice, Knockout, Cell Line, Tumor, Cell Proliferation, PTEN Phosphohydrolase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.